Dysregulation of positive transcription elongation factor B and myocardial hypertrophy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response.JAK-STAT · 2012
   Review
2. Isolation and functional characterization of P-TEFb-associated factors that control general and HIV-1 transcriptional elongation.Methods (San Diego, Calif.) · 2011
   Article

Corrections and comments

• Comment on
  Positive transcription elongation factor b activity in compensatory myocardial hypertrophy is regulated by cardiac lineage protein-1.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as